New stock news | Lingke Pharmaceutical submits second application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on June 15th, Lingke Pharmaceutical (Zhejiang) Co., Ltd. (referred to as Lingke Pharmaceutical) has submitted its application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC and China International Capital Corporation as the joint sponsors. The company had previously submitted a listing application to the Hong Kong Stock Exchange on November 30, 2025. According to the prospectus, Lingke Pharmaceutical was established in 2017 and focuses on developing small molecule inhibitors for the treatment of autoimmune and inflammatory diseases. As of the last practicable date, Lingke Pharmaceutical has two core products and seven additional clinical or preclinical development candidates. The core products of Lingke Pharmaceutical are LNK01001 and LNK01004. LNK01001 is an oral second-generation JAK1+ selective small molecule inhibitor, used for moderate to severe rheumatoid arthritis, moderate to severe ankylosing spondylitis, moderate to severe atopic dermatitis, and vitiligo. LNK01004 is a topical soft pan-JAK inhibitor, used for mild to moderate atopic dermatitis and other inflammatory skin diseases.